8-K: Klotho Neurosciences Secures $14.96M in Preferred Stock Sale

Klotho Neurosciences, Inc. has entered into an agreement to sell $14.96 million in Series C Preferred Stock to investor Sigma9 Capital, Ltd. in a private offering.

Summary

• Klotho Neurosciences, Inc. (KLTO) entered into a Securities Purchase Agreement with Sigma9 Capital, Ltd. on December 2, 2025.
• The company will issue and sell 3,400 shares of a new Series C Preferred Stock at a price of $4,400.00 per share.
• This transaction is expected to raise $14,960,000.00 for the company.
• Each Series C Preferred share is convertible, at the holder's option, into 10,000 shares of the company's common stock.
• Conversion is subject to limitations, including that the holder cannot own more than 9.99% of outstanding common stock post-conversion.
• Aggregate conversions by all Series C holders are limited to 19.99% of the company's issued and outstanding common stock as of the issuance date, until stockholder approval is obtained.
• Series C Preferred Stock holders are entitled to a liquidation preference equal to 111% of the original purchase price ($4,773.00 per share) upon any liquidation, merger, dissolution, or winding up.
• The sale was made in reliance upon the exemption from registration offered by Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D, indicating a private offering to an accredited investor.
• The closing of the purchase is subject to conditions, including the filing of the Certificate of Designation for the Series C Preferred Stock and the closing occurring on or before December 31, 2025.

Sentiment

Score: 7

Explanation: The company successfully secured a significant capital injection of nearly $15 million through a private placement of preferred stock. While this provides crucial funding, the terms of the Series C Preferred Stock, including its liquidation preference and potential future dilution upon conversion, introduce complexities and potential future impacts on common shareholders.

Positives

• Secured $14.96 million in new capital, providing funding for operations or strategic initiatives.
• The private placement structure avoids immediate dilution to existing common shareholders from a public offering.
• Attracted a sophisticated institutional investor, Sigma9 Capital, Ltd.

Negatives

• Potential future dilution for common shareholders upon conversion of the Series C Preferred Stock.
• The Series C Preferred Stock carries a liquidation preference of 111% of the original purchase price, placing preferred shareholders ahead of common shareholders in a liquidation event.
• The conversion limitations (9.99% individual, 19.99% aggregate without stockholder approval) could complicate future capital structure management or investor flexibility.

Risks

• Dilution Risk: Future conversion of Series C Preferred Stock into common stock will dilute the ownership percentage of existing common shareholders.
• Liquidation Preference: In the event of liquidation, Series C Preferred Stockholders are entitled to receive 111% of their original purchase price before common stockholders receive any distribution.
• Stockholder Approval Risk: The aggregate conversion limit of 19.99% of outstanding common stock requires stockholder approval to exceed, which may not be obtained, potentially limiting the investor's ability to fully convert.
• Regulatory Compliance Risk: The company must ensure compliance with Nasdaq rules regarding conversions and potential stockholder approval.
• Market Price Impact: The potential for a large number of common shares to be issued upon conversion could put downward pressure on the common stock price.

Future Outlook

The company anticipates the closing of this private placement by December 31, 2025, subject to standard closing conditions including the filing of the Certificate of Designation for the Series C Preferred Stock. Future conversions of the preferred stock are subject to stockholder approval to exceed certain thresholds and compliance with Nasdaq rules.

Industry Context

This capital raise provides Klotho Neurosciences, a company in the biotechnology/neurosciences sector, with additional funding, which is crucial for research, development, and operational expenses in a capital-intensive industry. Such private placements are common for growth-stage companies seeking to fund their pipeline without immediate public market pressures, though the specific terms of preferred stock can vary widely.

Comparison to Industry Standards

• NA The filing does not provide sufficient information to compare the terms of this specific capital raise (e.g., valuation, dilution impact relative to development stage) to industry benchmarks or comparable companies. The terms of preferred stock, including conversion ratios and liquidation preferences, are highly specific to the company's financial health, stage of development, and negotiation with the investor.

Corporate Governance

Stakeholder Impact

• Shareholders (Common): Potential for future dilution upon conversion of Series C Preferred Stock. Subordination to Series C Preferred Stock in liquidation.
• Investors (Series C Preferred): Gained a senior equity position with a liquidation preference and significant conversion rights, subject to limitations.
• Company: Received a substantial capital infusion to fund operations and strategic initiatives.

Next Steps

• Filing of the Certificate of Designation for Series C Preferred Stock.
• Closing of the purchase transaction on or before December 31, 2025.
• Potential future stockholder approval to allow conversion beyond the 19.99% aggregate common stock limit.

Key Dates

Recommendation

The capital raise provides essential funding for Klotho Neurosciences, which is a positive for its operational continuity and strategic objectives. However, the introduction of convertible preferred stock with a liquidation preference and potential future dilution for common shareholders warrants a cautious approach. Investors should hold to assess how the company utilizes this capital and the impact of future conversions on the common stock's value and ownership structure.

Keywords

Klotho Neurosciences, KLTO, Series C Preferred Stock, Private Placement, Capital Raise, Equity Financing, Convertible Preferred Stock, Sigma9 Capital, SEC Filing, 8-K, Neurosciences, Biotechnology